期刊文献+

阿帕替尼治疗晚期胃癌1例报告 被引量:7

Advanced Gastric Cancer Treated by Apatinib:One Case Report
原文传递
导出
摘要 2012年全球新诊断胃癌90万例,死亡50万例,仅次于肺癌和肝癌,居癌症死因的第3位,我国每年胃癌新发病例数居世界首位。大型Ⅲ期临床试验To GA研究所得出的晚期胃癌患者的中位生存期(median overall survival,mOS)为13.8个月,中位无进展生存期(median progression free survival,m PFS)为6.7个月。根据肿瘤的特征及分期,目前肿瘤治疗包括手术、化疗及放疗等,但由于大部分患者就诊时已属进展期胃癌,治疗效果并不理想。
出处 《肿瘤学杂志》 CAS 2016年第4期336-338,共3页 Journal of Chinese Oncology
  • 相关文献

参考文献6

二级参考文献74

  • 1Muhammed Ashraf Memon,Nick Butler,Breda Memon.The issue of lymphadenectomy during laparoscopic gastrectomy for gastric carcinoma[J].World Journal of Gastrointestinal Oncology,2010,2(2):65-67. 被引量:10
  • 2Kamangar F, Dores GM, Anderson WF. Patterns of cancer incidence, mortality, and prevalence across five continents: defining priorities to reduce cancer disparities in different geographic regions of the world. J Clin Oncol. 2006;24:2137-2150.[PubMed] [DOI].
  • 3Bickenbach K, Strong VE. Comparisons of Gastric Cancer Treatments: East vs. West. J Gastric Cancer. 2012;12:55-62.[PubMed] [DOI].
  • 4Wagner AD, Unverzagt S, Grothe W, Kleber G, Grothey A, Haerting J, Fleig WE. Chemotherapy for advanced gastric cancer. Cochrane Database Syst Rev. 2010;(3):CD004064.[PubMed].
  • 5Thuss-Patience PC, Kretzschmar A, Bichev D, Deist T, Hinke A, Breithaupt K, Dogan Y, Gebauer B, Schumacher G, Reichardt P. Survival advantage for irinotecan versus best supportive care as second-line chemotherapy in gastric cancer--a randomised phase III study of the Arbeitsgemeinschaft Internistische Onkologie (AIO). Eur J Cancer. 2011;47:2306-2314.[PubMed] [DOI].
  • 6Kang JH, Lee SI, Lim do H, Park KW, Oh SY, Kwon HC, Hwang IG, Lee SC, Nam E, Shin DB. Salvage chemotherapy for pretreated gastric cancer: a randomized phase III trial comparing chemotherapy plus best supportive care with best supportive care alone. J Clin Oncol. 2012;30:1513-1518.[PubMed].
  • 7Sasako M, Inoue M, Lin JT, Khor C, Yang HK, Ohtsu A. Gastric Cancer Working Group report. Jpn J Clin Oncol. 2010;40 Suppl 1:i28-i37.[PubMed] [DOI].
  • 8Ueda S, Hironaka S, Yasui H, Nishina T, Tsuda M, Tsumura T, Sugimoto N, Shimodaira H, Tokunaga S, Moriwaki T. Randomized phase III study of irinotecan (CPT-11) vs weekly paclitaxel (wPTX) for advanced gastric cancer (AGC) refractory to combination chemotherapy (CT) of fluoropyrimidine plus platinum (FP): WJOG4007 trial. J Clin Oncol. 2012;30 Suppl:abstr 4002.
  • 9Hasegawa H, Fujitani K, Nakazuru S, Hirao M, Mita E, Tsujinaka T. Optimal indications for second-line chemotherapy in advanced gastric cancer. Anticancer Drugs. 2012;23:465-470.[PubMed] [DOI].
  • 10Shitara K, Yatabe Y, Matsuo K, Sugano M, Kondo C, Takahari D, Ura T, Tajika M, Ito S, Muro K. Prognosis of patients with advanced gastric cancer by HER2 status and trastuzumab treatment. Gastric Cancer. 2012;Epub ahead of print.[PubMed] [DOI].

共引文献198

同被引文献76

引证文献7

二级引证文献143

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部